Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pandemic Perspectives

COVID-19’s impact after one year.

Pandemic Perspectives: A Lasting Impact On Medtech, But Not Dealmaking

The COVID-19 pandemic has fundamentally changed health care and the life sciences, KPMG analyst Kristin Pothier concludes in a new report on the medtech investment outlook.

Analysis Commercial Deals

Pandemic Perspectives: Riding The Waves Of Asia’s Healthtech Innovation Explosion

One year on, we’ve seen how the coronavirus prompted entrepreneurial instincts to surface in the medtech and healthtech sectors. Asia healthtech investor specialist HealthXCapital tells Medtech Insight about the changes that are likely to stick as in an industry that has seen the value of rapid responsiveness to acute need.

Coronavirus COVID-19 Commercial Financing

Pandemic Perspectives: How COVID Emergency Use Authorizations Could Reshape US FDA

From re-examining the FDA’s place in the broader US government to how fast and flexible it can be clearing therapies in non-emergency times, the COVID-19 EUA experience is expected to have a long-lasting impact on the agency. 

Coronavirus COVID-19 Drug Approval Standards

Pandemic Perspectives: Shifting Research Realities After COVID-19 Place Decentralized Trials Center Stage

Agreeing that decentralized trials are here to stay, experts discussed in a recent meeting ways in which the pharma research landscape is set to change. With nearly 85% of the industry at different stages of adoption, such trials have seen greater traction in the US, while stricter data privacy laws have hampered progress in Europe, ISCR’s annual conference heard.

Clinical Trials Research & Development

Pandemic Perspectives: COVID’s Unprecedented Experience With Emergency Use Authorizations

The US Food and Drug Administration's EUA pathway has seen more use in the therapeutic and vaccine space during the current pandemic than it has in its entire 16-year history and in many cases the potential eligible populations for the authorized products are far larger than past EUAs. Pink Sheet infographic compares details of past and present EUAs.

Coronavirus COVID-19 Review Pathway

Pandemic Perspectives: How COVID May Reshape US Emergency Use Authorizations

FDA policy experts Jesse Goodman, Mark McClellan, Peter Lurie, David Bowen, Patti Zettler, and Aaron Kesselheim suggest ideas and points to consider in using the COVID-19 experience to assess whether standards for EUAs should be adjusted. 

Coronavirus COVID-19 FDA

Pandemic Perspectives: EU/UK Coronavirus Vaccine And Treatment Progress At A Glance

The EU and the UK are going their own way when it comes to making COVID-19 vaccines and treatments available. The European Commission has chosen the full conditional marketing authorization path, while the UK, no longer a member of the EU, is taking the temporary authorization route. 

Approvals Coronavirus COVID-19

Pandemic Perspectives: COVID-19 Upended Drug Launches In Ways That Will Stick

Preliminary data from IQVIA suggest 2020 was one of the weakest in recent years for new launch trajectories although drug companies tell Scrip there are some lessons learned from promoting during the pandemic.

Launches Coronavirus COVID-19

Pandemic Perspectives: Cracks In Global Supply Chain Lead To Localization Trend

Weaknesses in the global pharmaceutical supply chain, exposed and exacerbated by the coronavirus pandemic, have led major markets to pursue localization policies aimed at bolstering domestic production capacity. But any significant transformation promises to take many years.

Manufacturing Policy

Pandemic Perspectives: What’s The New Normal For The Business Of Biopharma?

In Part 2 of Scrip’s roundtable, execs from Athira, Cartesian, Cyclacel, Tonix and VOZ Advisors discuss how the pandemic brought in new investors and triggered strategic shifts for the biopharma industry. 

Coronavirus COVID-19 Business Strategies

Pandemic Perspectives: R&D Lessons Learned From The COVID Year

The ways companies found to move forward during the challenging year also offer opportunities for industry to improve. During a roundtable discussion with Scrip, execs from Athira, Cartesian, Cyclacel, Tonix and VOZ Advisors weighed in on the adaptations they made and what changes they’ll stick with. 

Coronavirus COVID-19 Clinical Trials

Pandemic Perspectives: Remdesivir, Favipiravir’s Eventful Journeys In India A Year On

COVID-19 doesn't seem to be going away any time soon and antivirals remdesivir and favipiravir remain part of the treatment armamentarium. “Safety inventories” are in place for remdesivir in India, while a key physician anticipates an uptick in the use of favipiravir amid a surge in cases in some parts of the country.

India Commercial

Pandemic Perspectives: US FDA ACTT’s On Its Faith In Randomized Trials With Veklury Approval Despite WHO Study

US FDA has not deviated from its bedrock trust in the value of ‘statistically reliable’ endpoints amidst the COVID-19 pandemic, the Pink Sheet’s Drug Review Profile of Gilead’s Veklury shows.

Drug Review Profile Coronavirus COVID-19

Pandemic Perspectives: Veklury’s Clinical Development Timeline Compressed By Collaborative Review, Previous Research

Just five and half years elapsed between Gilead’s first remdesivir IND for Ebola virus and Veklury’s US FDA approval for COVID-19.

Drug Review Profile Drug Review
See All
UsernamePublicRestriction

Register